Propycil

Quick links to important sections

Propycil

Selected form

Method of action: Antithyroid, Thyroid Therapy

Treatment option: Hyperthyroidism, Thyrotoxicosis

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Propycil

Property Description
Active ingredient Propylthiouracil (PTU)
Form Tablet
Pharmacological class Antithyroid Drug (Thioamide)
General therapeutic purpose Control of an overactive thyroid gland (hyperthyroidism)
Origin Synthetic compound

1. What Type of Medicine is Propycil (Propylthiouracil)?

Propycil is the trade name for the established pharmaceutical entity Propylthiouracil (PTU), which is classified as a prescription-only antithyroid drug. Propylthiouracil belongs to the thioamide pharmacological class, a group of compounds utilized for their inhibitory effects on thyroid function. This classification confirms the drug's specialized role in managing thyroid conditions. Propylthiouracil is chemically a synthetic thiourea derivative, defining it as a product designed to medically manage disorders where the thyroid gland is overactive. The fundamental therapeutic purpose of Propycil is to provide a solution for controlling the excessive production of thyroid hormones, the core characteristic of conditions such as hyperthyroidism and thyrotoxicosis.

2. Composition and Form: What is Propylthiouracil Made Of?

The therapeutic effect of the medication is derived solely from its single active ingredient, Propylthiouracil. This active ingredient is formulated as a small, solid tablet designed for oral administration. This form ensures consistency for patient use and is typically favored over liquid preparations for long-term therapy. Propylthiouracil is a single-ingredient product, which ensures a focused action tied directly to thyroid regulation. The tablet structure includes inactive components, or excipients, necessary to form the compound and ensure stable and consistent delivery of the antithyroid drug through the digestive system.

3. How Does Propylthiouracil Generally Affect Thyroid Function?

Propylthiouracil functions as a thyroid inhibitor by providing chemical control over the synthesis of hormones within the thyroid gland, effectively acting as a restraint on its activity. Its main mechanism principle is to block hormone production by interfering with the chemical steps necessary to create new thyroid hormones (T3 and T4) within the gland. The use of such thioamides is a primary approach for controlling thyroid hormone output. By progressively restricting this synthesis, the medication gradually lowers the total concentration of active hormones circulating in the bloodstream. This action serves the general purpose of reversing the high-metabolic state associated with hyperthyroidism, helping to restore the body’s internal functions to a sustainable, normal balance.

What side effects are possible with Propycil?

Propylthiouracil (PTU) is associated with officially documented adverse reactions that range from common, generalized effects to serious, potentially fatal systemic reactions. The regulatory safety profile is dominated by the risk of Severe Liver Injury and Liver Failure, which has led to a special warning in official labeling. This reaction may occur at any time during therapy but is a particular concern during the first six months of treatment.

Another critical, life-threatening adverse reaction is Agranulocytosis (a severe reduction in white blood cells), which regulatory documents indicate typically occurs within the first three months of initiation.

System-Organ Class (SOC) Grouped Effects

Common adverse reactions are categorized across several systems:

  • Dermatological: Skin rash, hives (urticaria), pruritus, and hair loss (alopecia).
  • Musculoskeletal: Joint pain (Arthralgia) and muscle pain (Myalgia).
  • Gastrointestinal: Nausea, vomiting, and taste perversion.
  • Nervous System: Headache, dizziness, and tingling sensations (Paresthesias).

Serious, but rarer, reactions documented include various forms of Vasculitis (inflammation of blood vessels), aplastic anemia, and a lupus-like syndrome.

Safety Constraints in Specific Populations

Due to the documented risk of severe hepatotoxicity, Propylthiouracil is generally not recommended as first-line therapy for hyperthyroidism in pediatric patients. Specific safety constraints also apply to its use during pregnancy and require cautious dose selection for older adults.

Overdose and Emergency Response

The official regulatory profile for Propylthiouracil (Propycil) overdose describes acute manifestations and specific severe risks that mandate immediate emergency action. Acute presentations may involve gastrointestinal distress, including nausea, vomiting, and epigastric pain, as well as systemic symptoms like headache and drowsiness.

The most serious documented risks stem from potential toxicity to the blood and endocrine systems, leading to agranulocytosis (a severe blood disorder) and the development of hypothyroidism or goiter following repeated high-dose exposure. Over-dosage during pregnancy is specifically associated with the risk of congenital goiter in the fetus.

Seek immediate medical attention is the explicit regulatory requirement for any suspected or confirmed over-dosage, including contacting emergency services or a Poison Control Center immediately. Management is restricted to general symptomatic and supportive measures, as official labeling confirms no specific antidote is known for Propylthiouracil.

Required monitoring includes continuous observation of the patient's medical status and necessary laboratory testing, such as blood cell counts and thyroid function tests, to assess for severe hematologic toxicity.

Therapeutic Uses of Propycil

Main Uses of Propycil

Propycil contains the active substance propylthiouracil, which belongs to a group of medications known as antithyroid agents. Its primary function is to reduce the production of thyroid hormones within the thyroid gland.

This medication is primarily used to manage conditions characterized by an overactive thyroid, a state known medically as hyperthyroidism. By inhibiting the enzyme responsible for synthesizing thyroid hormones (thyroxine and triiodothyronine), it helps restore metabolic balance in the body.

Specific Clinical Applications

  • Graves' Disease: Propycil is used to treat this autoimmune disorder, which is the most common cause of hyperthyroidism. It helps control the excessive hormone production triggered by the immune system.
  • Toxic Multinodular Goiter: The medication is used when one or more nodules on the thyroid gland become overactive and produce surplus hormones.
  • Preparation for Surgery or Radioiodine Therapy: It is frequently administered to stabilize thyroid hormone levels before a patient undergoes a thyroidectomy (surgical removal of the thyroid) or radioactive iodine treatment. This ensures the patient is in a metabolic state that reduces the risk of complications during these procedures.
  • Thyroid Storm: In acute cases where thyroid hormone levels become dangerously high, Propycil may be used as part of a comprehensive management strategy to rapidly decrease hormone synthesis.

Benefits and Therapeutic Goals

The primary benefit of Propycil therapy is the normalization of the body's metabolic rate. When hyperthyroidism is successfully managed, the physiological strain caused by excessive thyroid hormones is diminished.

Key therapeutic goals include:

  • Reduction of Hyperthyroid Symptoms: By lowering hormone levels, the medication helps alleviate symptoms such as rapid or irregular heartbeat, excessive sweating, tremors, and nervousness.
  • Metabolic Stabilization: It assists in reversing unintended weight loss and improving heat tolerance.
  • Prevention of Long-term Complications: Maintaining thyroid hormones within a normal range helps protect the cardiovascular system and bone density, both of which can be adversely affected by prolonged hyperthyroidism.

Regulatory References

  1. National Institutes of Health (NIH) DailyMed service

Eligibility and Restrictions for Use

Who can and cannot use Propycil?

Propylthiouracil (Propycil) is classified by regulatory documents as a second-line agent for hyperthyroidism, meaning its use is restricted to specific patient groups where alternatives are unsuitable.

Eligibility Scope Status Defined by Regulatory Labeling
Populations for whom use is allowed Adult patients with hyperthyroidism who are intolerant of methimazole and for whom surgery or radioactive iodine therapy are not appropriate options.
Populations for whom use is contraindicated Patients with known hypersensitivity to the drug or its components. Patients with a history of severe adverse reactions (e.g., agranulocytosis). Patients with certain hereditary metabolic disorders. Breastfeeding women (contraindicated in some regions).
Age-related eligibility rules Not recommended for general use in pediatric patients due to the risk of severe liver injury. Use in children is reserved only for rare, specific circumstances where alternatives are unsuitable. Geriatric patients require cautious dose selection due to common decreased organ function.
Pregnancy eligibility status May be the preferred treatment in the first trimester. For the second and third trimesters, switching to an alternative medicine may be advisable due to maternal health risks.
Condition-specific rules Use requires caution in patients with existing hepatic impairment (liver disease) or renal impairment.

Connection to the overall eligibility profile: Official documents establish Propycil as a therapy that is reserved for patients who have already failed or cannot tolerate methimazole. Non-eligibility is explicitly stated for those with drug hypersensitivity, while age and pre-existing organ conditions are defined as circumstances requiring conditional use or exclusion.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Propylthiouracil (Propycil) interacts with several medicinal products primarily due to its effect on thyroid status and, in some cases, its direct influence on other drug systems, as documented in regulatory information.

Documented Drug Interactions

Co-administration with Oral Anticoagulants may increase their activity, potentially leading to an increased risk of bleeding. This effect is thought to be related to the drug's influence on Vitamin K activity.

Propylthiouracil must be discontinued at least three to four days before therapeutic administration of Radioactive Iodine (^131 I), as the antithyroid effect can reduce the thyroid gland's uptake of the isotope, impairing its intended therapeutic outcome.

Thyroid Status-Dependent Clearance

As Propylthiouracil works to restore a normal thyroid state (euthyroid state) from a hyperactive one, the clearance of certain co-administered drugs may decrease. This interaction pattern applies to Beta-adrenergic Blocking Agents (Beta-blockers), Digitalis Glycosides (like Digoxin), and Theophylline. The regulatory profile states that the change in thyroid function can result in a shift in the patient's exposure to these medicines.

Other Interaction Considerations

High intake of Iodine-rich foods or substances may officially impair the thyroid gland’s response to Propylthiouracil. Additionally, caution is noted in regulatory documents regarding co-administration with other medicinal products known to cause Agranulocytosis due to the potential for an additive risk of serious blood issues.

Mechanism of Action

Propycil, which is Propylthiouracil (PTU), is a thioureylene compound that selectively concentrates within the thyroid gland. Its primary mechanism involves two distinct enzyme inhibitor interactions.

First, PTU acts as a non-competitive inhibitor of thyroid peroxidase (TPO), the key enzyme in the organification and coupling steps of hormone synthesis. This interaction disrupts the oxidation of iodide ( I^-) to iodine ( I2) and subsequently prevents the iodination of tyrosine residues on the thyroglobulin protein, thereby arresting the formation of monoiodotyrosine (MIT) and diiodotyrosine (DIT). Downstream, this halts the coupling of MIT and DIT to form the precursors for thyroxine ( T4) and triiodothyronine ( T3).

Second, PTU functions as an inhibitor of type I 5'-deiodinase in peripheral tissues, a membrane-bound enzyme responsible for converting T4 to the more biologically active T3. This secondary action reduces the systemic concentration of circulating T3.

The combined molecular inhibition of TPO and 5'-deiodinase results in a system-level physiological consequence of reduced overall thyroid hormone output and activity.

Dosage and Administration Information

Administration and Dosage Principles

Propylthiouracil (Propycil) is formulated as a 50 mg tablet and is designated for oral administration. The usage protocol follows two distinct phases: an initial phase to establish control and a subsequent maintenance phase.

Treatment generally begins with an initial daily dose for adults, typically 300 mg, which is administered in three equally divided doses taken at approximate 8-hour intervals. For severe hyperthyroidism or very large goiters, the initial dose may be increased up to 900 mg daily.

Once thyroid function is controlled—a state often achieved within 1 to 2 months—the dosage is adjusted downwards to a maintenance dose of 100 mg to 150 mg daily. During this phase, the frequency may be reduced, sometimes allowing for once daily administration. The tablets can be taken with or without food.

Population and Procedural Rules

Specific dosing modifications are necessary for certain populations. Dose reduction is advised for patients with hepatic or renal impairment; a 50% dose reduction may be indicated for severe kidney impairment. Pediatric dosing is specified for children aged 6 years and older.

The official use protocol includes defined procedural steps: if a dose is missed, it should not be doubled to make up for the skipped administration. Furthermore, the medicine is routinely withdrawn 2 to 4 days prior to the scheduled administration of radioactive iodine therapy to ensure procedural efficacy.

Recent Clinical Evidence

Recent Clinical Evidence Overview

Clinical research on Propylthiouracil (PTU) has primarily focused on its role as an antithyroid agent, its comparative safety profile, and its use in specific patient populations, particularly during pregnancy and in acute thyrotoxicosis (thyroid storm).


Comparative Safety and Efficacy

Studies comparing PTU with methimazole (MMI), another antithyroid drug, have highlighted differences in their risk profiles. A key finding is the lower risk of congenital anomalies (birth defects) associated with PTU exposure compared to MMI exposure during the first trimester of pregnancy. This difference supports the use of PTU as a primary antithyroid option during this early stage.

Conversely, research has noted that PTU carries a higher risk of severe liver injury and acute liver failure in both adults and children, leading to regulatory warnings. Due to this risk, some studies suggest that MMI may be the preferred agent for non-pregnant adults and children, with PTU reserved for specific high-risk scenarios.


Use in Thyroid Storm and Radioiodine Therapy

  1. Thyroid Storm: PTU is often used in the management of severe, acute thyrotoxicosis (thyroid storm). This preference is due to PTU's unique action of inhibiting the peripheral conversion of the thyroid hormone T4 (thyroxine) to the more active T3 (triiodothyronine), which methimazole does not.
  2. Radioiodine Pretreatment: A randomized trial on patients with hyperthyroidism found that pretreatment with PTU before receiving radioiodine therapy may reduce the overall long-term cure rate of the radioiodine treatment. This potential effect is a consideration when planning sequential therapies.

Frequently Asked Questions (FAQ)

Common questions about Propycil (FAQ)


Q: Is Propycil the same as methimazole (Tapazole)?

A: Propylthiouracil (Propycil) and methimazole (Tapazole) are different agents used in the management of thyroid conditions. Both agents reduce thyroid hormone synthesis. Official information notes that Propylthiouracil has a distinct chemical action from methimazole.


Q: How quickly does Propycil start to work?

A: According to official product information, a noticeable effect may be observed within the first 24 to 36 hours of use. However, changes in laboratory measures are typically observed after one to three weeks of use.


Q: What are the most common side effects people mention online?

A: Regulatory documents indicate that minor cutaneous reactions (skin reactions) are among the most commonly reported adverse events. These include skin rash, pruritus (itching), and urticaria (hives), which often occur early in the course of treatment.


Q: Are there any foods or drinks I should avoid while using Propycil?

A: Official drug labels note that taking Propycil alongside a high intake of iodine-rich foods or substances may potentially interfere with the agent's expected activity. There is no consistent regulatory warning that mandates the avoidance of other specific foods or drinks.


Q: Is Propycil safe to use during pregnancy?

A: The use of Propylthiouracil during pregnancy is a complex medical decision. Regulatory evidence suggests that its use may be prioritized during the first trimester due to concerns about fetal abnormalities associated with an alternative agent. However, the treatment plan involves close monitoring throughout the entire pregnancy to minimize risks like fetal hypothyroidism or goiter.


Q: Are there different strengths or forms of Propycil?

A: According to official product documentation, the agent is typically formulated as a single strength 50 mg tablet designed for oral administration.


Q: Is Propycil used for conditions other than hyperthyroidism?

A: Propylthiouracil is indicated for hyperthyroidism and for the management of thyrotoxic crisis (thyroid storm).


Q: Why are routine blood tests important when taking Propycil?

A: Blood tests are required to monitor the patient's response to therapy and help detect rare but serious safety concerns. Monitoring includes regular checks of blood cell counts and liver function due to the potential for agranulocytosis (low white blood cells) and severe liver injury. These tests help identify serious adverse reactions.


Q: What is the difference between Propycil and other thyroid medications?

A: Propylthiouracil is an agent that helps manage thyroid hormone levels. This mechanism differs from that of thyroid hormone replacement therapies (like levothyroxine), which work by adding thyroid hormone back into the body.


Q: Is there any research evidence on Propycil's long-term effects?

A: Official regulatory documents mention that in studies of laboratory animals, continuous thyroid suppression for prolonged periods was associated with changes in the thyroid gland, including hyperplasia and carcinoma formation. The typical course of treatment for humans can last between 6 months and 3 years.


Q: How does Propycil affect my immune system?

A: Official safety information notes that Propylthiouracil may cause adverse reactions that involve the immune system. These reactions include vasculitis (inflammation of blood vessels) and a lupus-like syndrome, in addition to the risk of severe blood issues like agranulocytosis.


Q: Is Propycil treatment generally effective?

A: Propylthiouracil is an agent approved for use in hyperthyroidism. Clinical improvement is typically observed within a few weeks of starting treatment, and published data indicate that prolonged remission is reported in approximately 50% of cases following 1 to 2 years of treatment.


Q: What are the typical expectations for improvement with Propycil?

A: Objective signs of clinical improvement, which are measured in laboratory tests, are typically observed after one to three weeks of therapy. A state of normal thyroid function, known as the euthyroid state, is usually observed within 6 to 8 weeks.


Q: Is Propycil the same drug name globally?

A: The official chemical name of the active ingredient, Propylthiouracil, is consistent across the world. However, the trade name, Propycil, may vary depending on the country or region where the drug is marketed.


Q: Are there specific research studies that support its use in children?

A: Due to the risk of severe liver toxicity, Propylthiouracil is not approved by the FDA for general use in children. Its use in the pediatric population is limited to rare, specific circumstances where other treatment options are not suitable.


Q: Can Propycil cause weight changes?

A: Regulatory documents note that unexplained or rapid weight gain is a potential symptom. This can occur if the medication lowers the thyroid hormone levels too much, leading to hypothyroidism.


Q: Is it common to feel tired or fatigued while on Propycil?

A: Unusual tiredness or weakness is listed in official product information as a potential side effect. This may also be a symptom of hypothyroidism, which could develop if the medication dose is too high.


Q: How long do most people typically stay on Propycil?

A: Propylthiouracil is not a short-term treatment. The full course of therapy for hyperthyroidism typically lasts 12 to 18 months, although official guidance states that treatment can continue for up to 3 years.


Q: What happens when treatment with Propycil is stopped?

A: Treatment is typically withdrawn gradually and under close medical supervision. After stopping the drug, it is necessary to continue monitoring the patient for a potential relapse of hyperthyroidism, which can sometimes occur months or even years later.


Q: What should I know about Propycil and surgery?

A: Because Propylthiouracil may increase the risk of bleeding (hypoprothrombinemia), regulatory documents advise that monitoring of blood clotting ability, specifically prothrombin time, should be considered before any surgical procedures.


Q: Does Propycil affect my mood or cause anxiety?

A: Some drug information lists depression and agitation as potential side effects. While the precise incidence is often unknown, these mood-related changes are noted in regulatory safety data.


Q: Is Propycil considered a long-term medication?

A: Yes, Propylthiouracil is considered a long-term treatment option. Official guidelines indicate that a course of therapy for hyperthyroidism can range from 6 months to 3 years.


Q: Does alcohol have an interaction with Propycil?

A: Studies cited in medical literature suggest that short-term consumption of ethanol (alcohol) does not cause significant changes in how the body processes Propylthiouracil. Therefore, official documents do not typically require a dose adjustment for patients who drink alcohol.


Q: Is it normal to have a sore throat while taking Propycil?

A: Regulatory warnings advise that if a sore throat develops, the patient should seek immediate medical attention. A sore throat may be associated with a rare, serious adverse reaction known as agranulocytosis (a severe drop in white blood cells).


Q: Is Propycil available generically?

A: Yes, Propylthiouracil is the generic name of the active ingredient and is widely available as a generic drug.


Q: How often are follow-up appointments needed when taking Propycil?

A: The frequency of follow-up appointments and blood tests is individualized. Typically, thyroid function tests are checked every 4 to 6 weeks at the start of treatment. Once the dose is stable, this monitoring frequency is often reduced to every 3 to 6 months.


Q: Can I drive or operate machinery while taking Propycil?

A: Regulatory patient leaflets advise caution because Propylthiouracil may cause side effects like dizziness and sleepiness. Therefore, activities requiring alertness should be avoided until the patient knows how the medication affects them.


Q: Can Propycil affect my sleep?

A: Official safety information lists drowsiness or sleepiness as a potential side effect of Propylthiouracil.

How should Propycil be stored and disposed of?

How to Store and Dispose of Propycil?

Propylthiouracil (Propycil) tablets must be stored at controlled room temperature, maintaining a range between 20 C to 25 C (68 F to 77 F), with permitted brief temperature excursions. The medicine must be kept in a tightly closed container and protected from excessive heat, moisture, and must not be frozen.

Storage Protection

It is mandatory to store Propylthiouracil out of the reach of children to prevent accidental ingestion. The product should be kept in the original packaging to protect it from light where required.

Disposal

Unused or expired tablets must be disposed of according to local requirements. If a drug take-back program is unavailable, follow official guidance: do not flush the tablets down the toilet. Instead, mix the medicine with an undesirable substance, seal it in a container, and discard it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Propycil found in:

A-Z Index: